by Xcellerant Ventures | Jul 2, 2026 | Portfolio Company News
How a strategic acquisition is helping Xcellerant Ventures portfolio company Mu Medical accelerate its vision for the future of eye care. At Xcellerant Ventures, we believe some of the most impactful healthcare companies are built by identifying important problems,...
by Xcellerant Ventures | Jan 9, 2026 | Portfolio Company News
The consolidated entity will leverage AI and precision engineering to create a comprehensive ecosystem advancing drug delivery, home monitoring, and clinical intelligence. ROCHESTER, Minn., Jan. 9, 2026 /PRNewswire/ — Nanodropper, the leader in...
by Xcellerant Ventures | Sep 17, 2025 | Portfolio Company News
When patients think about their eye medications, they usually focus on the active ingredient, the drug that lowers pressure, treats infection, or relieves dryness. But what if the design of the eyedrop itself was just as important as the medication inside?...
by Xcellerant Ventures | Apr 17, 2025 | Portfolio Company News
Revolutionizing Glaucoma Treatment: Timolol Microdrops Prove Just as Effective—with Less Waste There’s exciting news in the world of eye health that could change how glaucoma is managed. A recent clinical study has found that Timolol microdrops are just as...
by Xcellerant Ventures | Mar 23, 2025 | Portfolio Company News
Big News: Nanodropper Officially Approved as a Class I Medical Device by the KFDA! We’re thrilled to share some game-changing news in the world of eye care—Nanodropper has officially been approved as a Class I medical device by the KFDA! This is...
